VLA Fundamental Analysis - VALNEVA SE

Fundamental Rating

VLA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. Both the profitability and financial health of VLA have multiple concerns. VLA is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

VLA had negative earnings in the past year.
VLA had a negative operating cash flow in the past year.
VLA had negative earnings in each of the past 5 years.
In multiple years VLA reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -26.86%, VLA is in line with its industry, outperforming 53.01% of the companies in the same industry.
With a Return On Equity value of -80.02%, VLA perfoms like the industry average, outperforming 54.22% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-26.86%
ROE	-80.02%
ROIC	N/A

ROA(3y)-15.85%

ROA(5y)-14.17%

ROE(3y)-50.34%

ROE(5y)-55.45%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 46.53%, VLA is in line with its industry, outperforming 45.78% of the companies in the same industry.
VLA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for VLA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	46.53%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.2%

GM growth 5Y-7.06%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VLA has more shares outstanding
The number of shares outstanding for VLA has been increased compared to 5 years ago.
The debt/assets ratio for VLA has been reduced compared to a year ago.

2.2 Solvency

VLA has an Altman-Z score of -0.72. This is a bad value and indicates that VLA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.72, VLA perfoms like the industry average, outperforming 45.78% of the companies in the same industry.
VLA has a Debt/Equity ratio of 0.89. This is a neutral value indicating VLA is somewhat dependend on debt financing.
VLA's Debt to Equity ratio of 0.89 is in line compared to the rest of the industry. VLA outperforms 45.78% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.89
Debt/FCF	N/A
Altman-Z	-0.72

ROIC/WACCN/A

WACC7.66%

2.3 Liquidity

VLA has a Current Ratio of 1.78. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
VLA's Current ratio of 1.78 is in line compared to the rest of the industry. VLA outperforms 43.37% of its industry peers.
VLA has a Quick Ratio of 1.36. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.36, VLA is in line with its industry, outperforming 42.17% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.78
Quick Ratio	1.36

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

VLA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1180.00%.
VLA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.89%.
VLA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.09% yearly.

EPS 1Y (TTM)-1180%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-271.43%

Revenue 1Y (TTM)19.89%

Revenue growth 3Y-21.31%

Revenue growth 5Y6.09%

Sales Q2Q%-35.76%

3.2 Future

The Earnings Per Share is expected to grow by 55.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 17.00% on average over the next years. This is quite good.

EPS Next Y-664.71%

EPS Next 2Y-114.88%

EPS Next 3Y109.43%

EPS Next 5Y55.11%

Revenue Next Year-6.69%

Revenue Next 2Y2.34%

Revenue Next 3Y27.3%

Revenue Next 5Y17%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VLA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as VLA's earnings are expected to grow with 109.43% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-114.88%

EPS Next 3Y109.43%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for VLA!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

VALNEVA SE

EPA:VLA (1/16/2026, 7:00:00 PM)

4.388

+0.12 (+2.81%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-20 2025-11-20/bmo

Earnings (Next)03-18 2026-03-18/amc

Inst Owners24.02%

Inst Owner ChangeN/A

Ins Owners0.21%

Ins Owner ChangeN/A

Market Cap377.00M

Revenue(TTM)274.97M

Net Income(TTM)-120.41M

Analysts81.82

Price Target7.28 (65.91%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-17%

Min EPS beat(2)-90.69%

Max EPS beat(2)56.68%

EPS beat(4)2

Avg EPS beat(4)-21.59%

Min EPS beat(4)-115.24%

Max EPS beat(4)62.87%

EPS beat(8)4

Avg EPS beat(8)-5.97%

EPS beat(12)6

Avg EPS beat(12)-29.73%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)-5.23%

Min Revenue beat(2)-26.86%

Max Revenue beat(2)16.4%

Revenue beat(4)2

Avg Revenue beat(4)2.94%

Min Revenue beat(4)-26.86%

Max Revenue beat(4)26.97%

Revenue beat(8)3

Avg Revenue beat(8)-2.55%

Revenue beat(12)7

Avg Revenue beat(12)17.96%

Revenue beat(16)9

Avg Revenue beat(16)99.55%

PT rev (1m)-6.93%

PT rev (3m)-4.13%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-2.44%

EPS NY rev (1m)-3.34%

EPS NY rev (3m)-12.37%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-11.78%

Revenue NY rev (1m)-1.37%

Revenue NY rev (3m)-10.41%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.37
P/FCF	N/A
P/OCF	N/A
P/B	2.51
P/tB	2.96
EV/EBITDA	N/A

EPS(TTM)-0.64

EYN/A

EPS(NY)-0.32

Fwd EYN/A

FCF(TTM)-0.21

FCFYN/A

OCF(TTM)-0.21

OCFYN/A

SpS3.2

BVpS1.75

TBVpS1.48

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.86%
ROE	-80.02%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	46.53%
FCFM	N/A

ROA(3y)-15.85%

ROA(5y)-14.17%

ROE(3y)-50.34%

ROE(5y)-55.45%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-4.2%

GM growth 5Y-7.06%

F-Score4

Asset Turnover0.61

Health

		Industry Rank	Sector Rank
Debt/Equity	0.89
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	3.08%
Cap/Sales	0.22%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.78
Quick Ratio	1.36
Altman-Z	-0.72

F-Score4

WACC7.66%

ROIC/WACCN/A

Cap/Depr(3y)101.58%

Cap/Depr(5y)231.17%

Cap/Sales(3y)9.04%

Cap/Sales(5y)14.31%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-1180%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-271.43%

EPS Next Y-664.71%

EPS Next 2Y-114.88%

EPS Next 3Y109.43%

EPS Next 5Y55.11%

Revenue 1Y (TTM)19.89%

Revenue growth 3Y-21.31%

Revenue growth 5Y6.09%

Sales Q2Q%-35.76%

Revenue Next Year-6.69%

Revenue Next 2Y2.34%

Revenue Next 3Y27.3%

Revenue Next 5Y17%

EBIT growth 1Y-162.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-269.56%

EBIT Next 3Y56.42%

EBIT Next 5Y30.38%

FCF growth 1Y91.45%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y90.46%

OCF growth 3YN/A

OCF growth 5YN/A

VALNEVA SE / VLA.PA FAQ

Can you provide the ChartMill fundamental rating for VALNEVA SE?

ChartMill assigns a fundamental rating of 2 / 10 to VLA.PA.

Can you provide the valuation status for VALNEVA SE?

ChartMill assigns a valuation rating of 1 / 10 to VALNEVA SE (VLA.PA). This can be considered as Overvalued.

Can you provide the profitability details for VALNEVA SE?

VALNEVA SE (VLA.PA) has a profitability rating of 1 / 10.

How financially healthy is VALNEVA SE?

The financial health rating of VALNEVA SE (VLA.PA) is 3 / 10.

VALNEVA SE (VLA.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

VALNEVA SE / VLA.PA FAQ

Can you provide the ChartMill fundamental rating for VALNEVA SE?

Can you provide the valuation status for VALNEVA SE?

Can you provide the profitability details for VALNEVA SE?

How financially healthy is VALNEVA SE?